Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bempedoic acid - Esperion Therapeutics

Next Previous
Search
Drug Profile

Bempedoic acid - Esperion Therapeutics

Alternative Names: ESP-55016; ETC-1002; NEXLETOL; NILEMDO; Nilemdo

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Esperion Therapeutics
  • Developer Daiichi Sankyo Europe; Esperion Therapeutics; Otsuka Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia
  • Registered Cardiovascular disorders
  • Preregistration Hyperlipoproteinaemia type IIa
  • No development reported Hypertension

Most Recent Events

  • 20 Mar 2025 Esperion announced meetings with the US FDA it has gained alignment on a regulatory path forward for initiating Phase 3 studies of bempedoic acid
  • 20 Mar 2025 Esperion aligns with US FDA plans to initiate a phase III trial for Bempedoic acid in pediatric heterozygous and homozygous familial hypercholesterolemia (In children, Monotherapy, Combination therapy) in 2025
  • 20 Mar 2025 Esperion plans New Drug Applications for Hypercholesterolemia in Australia and Israel by in the first half of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top